Cargando…
Subtyping of Group 3/4 medulloblastoma as a potential prognostic biomarker among patients treated with reduced dose of craniospinal irradiation: a Japanese Pediatric Molecular Neuro-Oncology Group study
BACKGROUND: One of the most significant challenges in patients with medulloblastoma is reducing the dose of craniospinal irradiation (CSI) to minimize neurological sequelae in survivors. Molecular characterization of patients receiving lower than standard dose of CSI therapy is important to facilita...
Autores principales: | Fukuoka, Kohei, Kurihara, Jun, Shofuda, Tomoko, Kagawa, Naoki, Yamasaki, Kai, Ando, Ryo, Ishida, Joji, Kanamori, Masayuki, Kawamura, Atsufumi, Park, Young-Soo, Kiyotani, Chikako, Akai, Takuya, Keino, Dai, Miyairi, Yosuke, Sasaki, Atsushi, Hirato, Junko, Inoue, Takeshi, Nakazawa, Atsuko, Koh, Katsuyoshi, Nishikawa, Ryo, Date, Isao, Nagane, Motoo, Ichimura, Koichi, Kanemura, Yonehiro |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10521425/ https://www.ncbi.nlm.nih.gov/pubmed/37749662 http://dx.doi.org/10.1186/s40478-023-01652-4 |
Ejemplares similares
-
MEDB-30. Subclassification of Group 3/4 medulloblastoma as a potential prognostic biomarker to reduce the dose of craniospinal irradiation in patients with metastatic tumors: A Japanese Pediatric Molecular Neuro-Oncology Group study
por: Fukuoka, Kohei, et al.
Publicado: (2022) -
MPC-6 Clinical significance of whole chromosomal aberration signatures in non-metastatic medulloblastomas treated with 18Gy of craniospinal irradiation
por: Fukuoka, Kohei, et al.
Publicado: (2021) -
MBRS-38. MOLECULAR CLASSIFICATION AND CLINICAL CHARACTERISTICS OF 236 MEDULLOBLASTOMAS IN JAPAN
por: Kanemura, Yonehiro, et al.
Publicado: (2020) -
MPC-02 REVIEW OF MEDULLOBLASTOMA FOR THE ASSESSMENT OF CONSENSUS IN PATHOLOGICAL DIAGNOSIS USING JPMNG CASES
por: Sasaki, Atsushi, et al.
Publicado: (2019) -
PATH-28. MOLECULAR DIAGNOSIS FOR CENTRAL DIAGNOSIS OF BRAIN TUMORS FROM 2016 TO 2019— A REPORT FROM THE JAPAN CHILDREN’S CANCER GROUP (JCCG)
por: Nakano, Yoshiko, et al.
Publicado: (2020)